Advertisement
Advertisement
November 25, 2024
Boston Scientific to Acquire Intera Oncology
November 25, 2024—Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Intera Oncology Inc. Boston Scientific stated that the acquisition expands its interventional oncology offerings with a complementary therapy to treat liver-dominant metastases.
The company did not disclose specific terms of the transaction, which it expects to complete in the first half of 2025, subject to closing conditions.
According to the press release, Intera Oncology is a privately held medical device company that provides the Intera 3000 hepatic artery infusion (HAI) pump and the chemotherapy drug floxuridine, which are approved by the FDA. The Intera 3000 is used to administer HAI therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer.
Boston Scientific stated that the Intera 3000 pump is implanted under the skin and a connected catheter is placed in the hepatic artery, which supplies the liver with oxygenated blood. The pump then provides a continuous flow of floxuridine directly into the liver to treat tumors that have metastasized, most commonly from the colon.
Advertisement
Advertisement
